Beedassy A, Cardi G
Division of Hematology/Oncology, Medical College of Pennsylvania-Hahnemann University Cancer Center, Philadelphia, USA.
Semin Oncol. 1999 Aug;26(4):428-38.
In the United States, prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer death in men. Prostate cancer is a rare disease before age 40; however, the prevalence increases quickly to 80% by the age of 80, and with increasing life expectancy, hormone-refractory prostate cancer (HRPC) will soon represent the most common cancer in the male population in the United States and other Western countries. The evolution of early prostate cancer is variable and extends over many years; some tumors progress slowly or not at all, whereas others may progress more rapidly and be fatal after a few years. A widely held view is that chemotherapy has no role in HRPC because no single agent or combination has been shown to prolong survival in a randomized trial. This concept may be obsolete, as preliminary results for a number of approaches, mostly derived from laboratory observations, show that prostate cancers are not as resistant to chemotherapy as traditionally believed. The population of early "geriatric" HRPC patients is rapidly increasing, posing an even greater challenge to oncologists in coping with this difficult-to-manage patient population. In this article, we analyze the most novel chemotherapeutic combinations for the treatment of HRPC in otherwise healthy elderly men.
在美国，前列腺癌是最常被诊断出的癌症，也是男性癌症死亡的第二大主要原因。前列腺癌在40岁之前是一种罕见疾病；然而，其患病率在80岁时迅速上升至80%，并且随着预期寿命的增加，激素难治性前列腺癌（HRPC）很快将成为美国和其他西方国家男性人群中最常见的癌症。早期前列腺癌的发展具有变异性，会持续多年；一些肿瘤进展缓慢或根本不进展，而另一些可能进展更快，并在几年后致命。一种广泛持有的观点是，化疗在HRPC中不起作用，因为在随机试验中没有单一药物或联合用药被证明能延长生存期。这一观念可能过时了，因为一些主要来自实验室观察的方法的初步结果表明，前列腺癌对化疗的耐药性并不像传统认为的那样强。早期“老年”HRPC患者群体正在迅速增加，这给肿瘤学家应对这一难以管理的患者群体带来了更大的挑战。在本文中，我们分析了用于治疗其他方面健康的老年男性HRPC的最新化疗联合方案。
